NEWARK, NJ -- (Marketwire) -- 07/12/12 -- Actinium Pharmaceuticals Inc. (API), a leading targeted payload, cancer treatment company, is pleased to announce the launch of its newly revamped website. The site can be accessed at www.actiniumpharmaceuticals.com.
"As we continue to make progress and further our development plans we felt it was prudent to upgrade our website," said Dragan Cicic, M.D., CEO of Actinium Pharmaceuticals. "We look forward to continuing to announce further corporate developments as we make additional progress."
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a U.S. based biopharmaceutical company that develops innovative targeted payload immunotherapeutics based on its radiopharmaceutical expertise and its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.
Actinium Pharmaceuticals develops novel drugs for the treatment of blood borne and metastatic cancers. Its Actimab-A drug candidate is in a Phase I/II clinical trial in patients with acute myeloid leukemia over the age of 60. The Company has recently in-licensed Iomab-B, indicated for the conditioning of bone marrow in order to prepare patients with certain blood cancers for hematopoietic stem cell transplantation. A number of Phase II clinical trials with Iomab-B under a physician IND are ongoing at the Fred Hutchinson Cancer Research Center in Seattle. API is further developing Iomab-B and will sponsor pivotal clinical trials as the next step towards seeking commercial approval.
About the Web Site
The site provides an information platform for patients, physicians and investors in an easy to navigate format.
The aims of the site are to allow visitors to gain a comprehensive understanding of the Company's drug candidates and provide an industry leading resource for information on targeted payload therapies. Viewers can learn about the clinical trials with Actinium's drug candidates and the science behind them. In addition, the web site offers links to major peer reviewed publications on Actinium Pharmaceuticals' technology and a wider background on targeted payload therapy approaches. Web site visitors will have an ability to follow the progress of the drug candidates and Company's development in the News and Events sections. Current and potential investors will have the ability to download the latest information on the Company in the Investor section. Patients and other interested parties will be able to learn more about API's products and clinical trials in the Patients section.
"Our new site offers a clear explanation of the complex, cutting edge technology applied in our drug candidates for the treatment of the deadliest forms of cancer," said Dragan Cicic, MD, CEO of Actinium Pharmaceuticals. "Most importantly, it allows patients with currently incurable diseases to learn about our ongoing and planned clinical trials."
In keeping with Actinium Pharmaceuticals' mission to provide treatment for currently incurable diseases through collaboration with patients, physicians, scientists and other constituencies, the new website also offers multiple ways of contacting the Company. All the inputs will be carefully reviewed and will serve as a basis for further development of the web site. The ultimate goal is to eventually expand the web site into a forum for patients, physicians and other stake holders to share information, ideas and recommendations.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or Contact:
Dr. Dragan Cicic, MD
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
ProActive Capital Group, LLC
Tel: (646) 863-6341
Dennis S. Dobson Jr.
Tel: (203) 258-0150
Most Popular Stories
- Cantwell Targets Gender Gap in Small-Business Loans
- Americans Still Pessimistic Despite Economic Growth
- Parra Joins Exclusive Club of Hispanic CEOs
- Axxis Solutions Appoints Benites as CEO
- Apple to Unveil New Items on Sept. 9
- Pending Home Sales in U.S. Rise in Hopeful Sign
- Visual Search Sounds Cool, Remains Elusive
- Texans Look for Perry-Cruz Showdown in 2016
- Josh Gordon Loses Appeal, Out for Season
- Chrysler Gets Nod as a Top Employer for Hispanic Women